Koninklijke Philips N.V. (PHG) Stock Competitors & Peer Comparison

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PHG is priced at $25.99, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PHG's ROE is +0.09%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PHG is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BSX-PA's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ABT has a market cap of 158B. Regarding current trading prices, PHG is priced at $25.99, while ABT trades at $90.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ABT's P/E ratio is 25.41. In terms of profitability, PHG's ROE is +0.09%, compared to ABT's ROE of +0.12%. Regarding short-term risk, PHG is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ABT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ISRG has a market cap of 148.4B. Regarding current trading prices, PHG is priced at $25.99, while ISRG trades at $418.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ISRG's P/E ratio is 50.78. In terms of profitability, PHG's ROE is +0.09%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, PHG is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ISRG's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SYK has a market cap of 115.4B. Regarding current trading prices, PHG is priced at $25.99, while SYK trades at $301.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SYK's P/E ratio is 34.81. In terms of profitability, PHG's ROE is +0.09%, compared to SYK's ROE of +0.15%. Regarding short-term risk, PHG is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SYK's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, PHG is priced at $25.99, while MDT trades at $81.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas MDT's P/E ratio is 21.97. In terms of profitability, PHG's ROE is +0.09%, compared to MDT's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check MDT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BSX has a market cap of 72.6B. Regarding current trading prices, PHG is priced at $25.99, while BSX trades at $48.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BSX's P/E ratio is 20.43. In terms of profitability, PHG's ROE is +0.09%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PHG is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BSX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BRKRP has a market cap of 67.4B. Regarding current trading prices, PHG is priced at $25.99, while BRKRP trades at $460.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BRKRP's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.09%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, PHG is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check BRKRP's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, PHG is priced at $25.99, while EW trades at $87.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas EW's P/E ratio is 47.26. In terms of profitability, PHG's ROE is +0.09%, compared to EW's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check EW's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, RMD has a market cap of 28.2B. Regarding current trading prices, PHG is priced at $25.99, while RMD trades at $194.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas RMD's P/E ratio is 18.74. In terms of profitability, PHG's ROE is +0.09%, compared to RMD's ROE of +0.24%. Regarding short-term risk, PHG is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check RMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, DXCM has a market cap of 28B. Regarding current trading prices, PHG is priced at $25.99, while DXCM trades at $72.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas DXCM's P/E ratio is 31.15. In terms of profitability, PHG's ROE is +0.09%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, PHG is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check DXCM's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, PHG is priced at $25.99, while STE trades at $212.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas STE's P/E ratio is 26.76. In terms of profitability, PHG's ROE is +0.09%, compared to STE's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check STE's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PHG is priced at $25.99, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PHG's ROE is +0.09%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PHG is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check ABMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ZBH has a market cap of 16.8B. Regarding current trading prices, PHG is priced at $25.99, while ZBH trades at $86.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ZBH's P/E ratio is 22.46. In terms of profitability, PHG's ROE is +0.09%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PHG is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ZBH's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, PHG is priced at $25.99, while SNN trades at $30.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SNN's P/E ratio is 21.57. In terms of profitability, PHG's ROE is +0.09%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PHG is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SNN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, PHG is priced at $25.99, while PEN trades at $320.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas PEN's P/E ratio is 74.06. In terms of profitability, PHG's ROE is +0.09%, compared to PEN's ROE of +0.12%. Regarding short-term risk, PHG is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check PEN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PHG is priced at $25.99, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PHG's ROE is +0.09%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PHG is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check SWAV's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, PHG is priced at $25.99, while ALGN trades at $168.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ALGN's P/E ratio is 28.33. In terms of profitability, PHG's ROE is +0.09%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ALGN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, PHG is priced at $25.99, while GMED trades at $80.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas GMED's P/E ratio is 18.69. In terms of profitability, PHG's ROE is +0.09%, compared to GMED's ROE of +0.13%. Regarding short-term risk, PHG is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check GMED's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, PHG is priced at $25.99, while PODD trades at $146.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas PODD's P/E ratio is 34.29. In terms of profitability, PHG's ROE is +0.09%, compared to PODD's ROE of +0.21%. Regarding short-term risk, PHG is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check PODD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PHG is priced at $25.99, while MASI trades at $178.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas MASI's P/E ratio is 44.28. In terms of profitability, PHG's ROE is +0.09%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PHG is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check MASI's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, PHG is priced at $25.99, while BRKR trades at $59.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BRKR's P/E ratio is -249.83. In terms of profitability, PHG's ROE is +0.09%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, PHG is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BRKR's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BIO-B has a market cap of 8.7B. Regarding current trading prices, PHG is priced at $25.99, while BIO-B trades at $321.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BIO-B's P/E ratio is 53.40. In terms of profitability, PHG's ROE is +0.09%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, PHG is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check BIO-B's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, PHG is priced at $25.99, while BIO trades at $307.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BIO's P/E ratio is 51.06. In terms of profitability, PHG's ROE is +0.09%, compared to BIO's ROE of +0.02%. Regarding short-term risk, PHG is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BIO's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, PHG is priced at $25.99, while GKOS trades at $121.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas GKOS's P/E ratio is -36.87. In terms of profitability, PHG's ROE is +0.09%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, PHG is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check GKOS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PHG is priced at $25.99, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas NARI's P/E ratio is -59.24. In terms of profitability, PHG's ROE is +0.09%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PHG is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check NARI's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, PHG is priced at $25.99, while LIVN trades at $73.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas LIVN's P/E ratio is 37.61. In terms of profitability, PHG's ROE is +0.09%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, PHG is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check LIVN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PHG is priced at $25.99, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PHG's ROE is +0.09%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PHG is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check AXNX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, PHG is priced at $25.99, while IRTC trades at $107.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas IRTC's P/E ratio is -126.29. In terms of profitability, PHG's ROE is +0.09%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check IRTC's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, PHG is priced at $25.99, while ITGR trades at $92.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ITGR's P/E ratio is 23.01. In terms of profitability, PHG's ROE is +0.09%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, PHG is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ITGR's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, PHG is priced at $25.99, while TMDX trades at $71.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas TMDX's P/E ratio is 16.33. In terms of profitability, PHG's ROE is +0.09%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, PHG is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check TMDX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, PHG is priced at $25.99, while AXGN trades at $42.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas AXGN's P/E ratio is -66.23. In terms of profitability, PHG's ROE is +0.09%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check AXGN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, PHG is priced at $25.99, while ESTA trades at $76.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ESTA's P/E ratio is -52.03. In terms of profitability, PHG's ROE is +0.09%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, PHG is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ESTA's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PHG is priced at $25.99, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PHG's ROE is +0.09%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check NUVA's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, PHG is priced at $25.99, while UFPT trades at $224.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas UFPT's P/E ratio is 25.54. In terms of profitability, PHG's ROE is +0.09%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PHG is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check UFPT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, PHG is priced at $25.99, while PRCT trades at $27.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas PRCT's P/E ratio is -14.75. In terms of profitability, PHG's ROE is +0.09%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, PHG is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check PRCT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, PHG is priced at $25.99, while IART trades at $17.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas IART's P/E ratio is -2.71. In terms of profitability, PHG's ROE is +0.09%, compared to IART's ROE of -0.48%. Regarding short-term risk, PHG is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check IART's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, PHG is priced at $25.99, while BFLY trades at $5.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BFLY's P/E ratio is -17.30. In terms of profitability, PHG's ROE is +0.09%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, PHG is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BFLY's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $25.99, while TNDM trades at $19.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas TNDM's P/E ratio is -14.19. In terms of profitability, PHG's ROE is +0.09%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, PHG is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check TNDM's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $25.99, while AHCO trades at $9.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas AHCO's P/E ratio is -16.47. In terms of profitability, PHG's ROE is +0.09%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, PHG is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check AHCO's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $25.99, while ENOV trades at $22.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ENOV's P/E ratio is -1.15. In terms of profitability, PHG's ROE is +0.09%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, PHG is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ENOV's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $25.99, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PHG's ROE is +0.09%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PHG is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check HSKA's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $25.99, while ATEC trades at $7.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ATEC's P/E ratio is -9.54. In terms of profitability, PHG's ROE is +0.09%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, PHG is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ATEC's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $25.99, while INSP trades at $42.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas INSP's P/E ratio is 9.58. In terms of profitability, PHG's ROE is +0.09%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PHG is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check INSP's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $25.99, while IRMD trades at $93.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas IRMD's P/E ratio is 51.13. In terms of profitability, PHG's ROE is +0.09%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, PHG is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check IRMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $25.99, while AVNS trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas AVNS's P/E ratio is -15.62. In terms of profitability, PHG's ROE is +0.09%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PHG is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check AVNS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $25.99, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SILK's P/E ratio is -18.96. In terms of profitability, PHG's ROE is +0.09%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PHG is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check SILK's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $25.99, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas FNA's P/E ratio is -19.83. In terms of profitability, PHG's ROE is +0.09%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PHG is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check FNA's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $25.99, while CNMD trades at $35.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CNMD's P/E ratio is 19.84. In terms of profitability, PHG's ROE is +0.09%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CNMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, PHG is priced at $25.99, while AORT trades at $20.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas AORT's P/E ratio is 83.32. In terms of profitability, PHG's ROE is +0.09%, compared to AORT's ROE of +0.03%. Regarding short-term risk, PHG is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check AORT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PHG is priced at $25.99, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CSII's P/E ratio is -20.83. In terms of profitability, PHG's ROE is +0.09%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PHG is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check CSII's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, INMD has a market cap of 828.2M. Regarding current trading prices, PHG is priced at $25.99, while INMD trades at $13.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas INMD's P/E ratio is 10.09. In terms of profitability, PHG's ROE is +0.09%, compared to INMD's ROE of +0.13%. Regarding short-term risk, PHG is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check INMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, LMRI has a market cap of 791.7M. Regarding current trading prices, PHG is priced at $25.99, while LMRI trades at $8.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas LMRI's P/E ratio is -21.13. In terms of profitability, PHG's ROE is +0.09%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, PHG is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check LMRI's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SSII has a market cap of 768.5M. Regarding current trading prices, PHG is priced at $25.99, while SSII trades at $3.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SSII's P/E ratio is -76.80. In terms of profitability, PHG's ROE is +0.09%, compared to SSII's ROE of -0.23%. Regarding short-term risk, PHG is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SSII's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, PHG is priced at $25.99, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CRY's P/E ratio is 425.71. In terms of profitability, PHG's ROE is +0.09%, compared to CRY's ROE of +0.03%. Regarding short-term risk, PHG is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CRY's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CBLL has a market cap of 711.4M. Regarding current trading prices, PHG is priced at $25.99, while CBLL trades at $18.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CBLL's P/E ratio is -11.57. In terms of profitability, PHG's ROE is +0.09%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, PHG is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CBLL's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SIBN has a market cap of 659.9M. Regarding current trading prices, PHG is priced at $25.99, while SIBN trades at $14.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SIBN's P/E ratio is -38.15. In terms of profitability, PHG's ROE is +0.09%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, PHG is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SIBN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PHG is priced at $25.99, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PHG's ROE is +0.09%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, PHG is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check SRDX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BVS has a market cap of 589.4M. Regarding current trading prices, PHG is priced at $25.99, while BVS trades at $8.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BVS's P/E ratio is 21.22. In terms of profitability, PHG's ROE is +0.09%, compared to BVS's ROE of +0.16%. Regarding short-term risk, PHG is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BVS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PHG is priced at $25.99, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas APEN's P/E ratio is -9.43. In terms of profitability, PHG's ROE is +0.09%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PHG is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check APEN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, TCMD has a market cap of 567.7M. Regarding current trading prices, PHG is priced at $25.99, while TCMD trades at $25.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas TCMD's P/E ratio is 28.93. In terms of profitability, PHG's ROE is +0.09%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check TCMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BWAY has a market cap of 559.7M. Regarding current trading prices, PHG is priced at $25.99, while BWAY trades at $14.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BWAY's P/E ratio is 64.86. In terms of profitability, PHG's ROE is +0.09%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, PHG is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BWAY's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CTKB has a market cap of 559.2M. Regarding current trading prices, PHG is priced at $25.99, while CTKB trades at $4.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CTKB's P/E ratio is -7.47. In terms of profitability, PHG's ROE is +0.09%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CTKB's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CERS has a market cap of 559M. Regarding current trading prices, PHG is priced at $25.99, while CERS trades at $2.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CERS's P/E ratio is -55.80. In terms of profitability, PHG's ROE is +0.09%, compared to CERS's ROE of -0.15%. Regarding short-term risk, PHG is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CERS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, NPCE has a market cap of 556.4M. Regarding current trading prices, PHG is priced at $25.99, while NPCE trades at $16.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas NPCE's P/E ratio is -25.11. In terms of profitability, PHG's ROE is +0.09%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, PHG is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check NPCE's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PHG is priced at $25.99, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PHG's ROE is +0.09%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, PHG is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check ZIMV's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, PACB has a market cap of 506.3M. Regarding current trading prices, PHG is priced at $25.99, while PACB trades at $1.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas PACB's P/E ratio is -3.98. In terms of profitability, PHG's ROE is +0.09%, compared to PACB's ROE of -4.88%. Regarding short-term risk, PHG is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check PACB's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, PMI has a market cap of 498.9M. Regarding current trading prices, PHG is priced at $25.99, while PMI trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas PMI's P/E ratio is -0.42. In terms of profitability, PHG's ROE is +0.09%, compared to PMI's ROE of +4.99%. Regarding short-term risk, PHG is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check PMI's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, LAB has a market cap of 488M. Regarding current trading prices, PHG is priced at $25.99, while LAB trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas LAB's P/E ratio is -9.62. In terms of profitability, PHG's ROE is +0.09%, compared to LAB's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check LAB's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, KIDS has a market cap of 464.9M. Regarding current trading prices, PHG is priced at $25.99, while KIDS trades at $18.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas KIDS's P/E ratio is -10.77. In terms of profitability, PHG's ROE is +0.09%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, PHG is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check KIDS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, VREX has a market cap of 440.4M. Regarding current trading prices, PHG is priced at $25.99, while VREX trades at $10.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas VREX's P/E ratio is -5.23. In terms of profitability, PHG's ROE is +0.09%, compared to VREX's ROE of -0.18%. Regarding short-term risk, PHG is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check VREX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CLPT has a market cap of 429.5M. Regarding current trading prices, PHG is priced at $25.99, while CLPT trades at $14.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CLPT's P/E ratio is -14.32. In terms of profitability, PHG's ROE is +0.09%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, PHG is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CLPT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, OFIX has a market cap of 416.7M. Regarding current trading prices, PHG is priced at $25.99, while OFIX trades at $10.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas OFIX's P/E ratio is -6.87. In terms of profitability, PHG's ROE is +0.09%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, PHG is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check OFIX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, VMD has a market cap of 377.2M. Regarding current trading prices, PHG is priced at $25.99, while VMD trades at $9.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas VMD's P/E ratio is 26.59. In terms of profitability, PHG's ROE is +0.09%, compared to VMD's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check VMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, DCTH has a market cap of 372.5M. Regarding current trading prices, PHG is priced at $25.99, while DCTH trades at $10.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas DCTH's P/E ratio is 1079.00. In terms of profitability, PHG's ROE is +0.09%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, PHG is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check DCTH's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, AVR has a market cap of 355M. Regarding current trading prices, PHG is priced at $25.99, while AVR trades at $9.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas AVR's P/E ratio is -4.35. In terms of profitability, PHG's ROE is +0.09%, compared to AVR's ROE of -1.24%. Regarding short-term risk, PHG is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check AVR's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ICCM has a market cap of 347.8M. Regarding current trading prices, PHG is priced at $25.99, while ICCM trades at $5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ICCM's P/E ratio is -21.54. In terms of profitability, PHG's ROE is +0.09%, compared to ICCM's ROE of -2.12%. Regarding short-term risk, PHG is less volatile compared to ICCM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ICCM's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, MASS has a market cap of 333.5M. Regarding current trading prices, PHG is priced at $25.99, while MASS trades at $8.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas MASS's P/E ratio is -9.09. In terms of profitability, PHG's ROE is +0.09%, compared to MASS's ROE of -0.26%. Regarding short-term risk, PHG is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check MASS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PHG is priced at $25.99, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PHG's ROE is +0.09%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, PHG is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check SMLR's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ELMD has a market cap of 305.3M. Regarding current trading prices, PHG is priced at $25.99, while ELMD trades at $36.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ELMD's P/E ratio is 31.51. In terms of profitability, PHG's ROE is +0.09%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, PHG is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ELMD's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SENS has a market cap of 292.8M. Regarding current trading prices, PHG is priced at $25.99, while SENS trades at $7.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SENS's P/E ratio is -3.56. In terms of profitability, PHG's ROE is +0.09%, compared to SENS's ROE of -1.30%. Regarding short-term risk, PHG is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SENS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CATX has a market cap of 250.3M. Regarding current trading prices, PHG is priced at $25.99, while CATX trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CATX's P/E ratio is -2.30. In terms of profitability, PHG's ROE is +0.09%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PHG is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CATX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SGHT has a market cap of 250.3M. Regarding current trading prices, PHG is priced at $25.99, while SGHT trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SGHT's P/E ratio is -6.57. In terms of profitability, PHG's ROE is +0.09%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, PHG is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SGHT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PHG is priced at $25.99, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas MGRM's P/E ratio is -11.11. In terms of profitability, PHG's ROE is +0.09%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, PHG is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check MGRM's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, TMCI has a market cap of 239.4M. Regarding current trading prices, PHG is priced at $25.99, while TMCI trades at $3.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas TMCI's P/E ratio is -3.84. In terms of profitability, PHG's ROE is +0.09%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, PHG is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check TMCI's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PHG is priced at $25.99, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PHG's ROE is +0.09%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PHG is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check NVRO's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, RXST has a market cap of 211.1M. Regarding current trading prices, PHG is priced at $25.99, while RXST trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas RXST's P/E ratio is -4.51. In terms of profitability, PHG's ROE is +0.09%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PHG is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check RXST's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, PHG is priced at $25.99, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas EYES's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.09%, compared to EYES's ROE of -2.64%. Regarding short-term risk, PHG is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check EYES's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, PROF has a market cap of 205.8M. Regarding current trading prices, PHG is priced at $25.99, while PROF trades at $6.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas PROF's P/E ratio is -5.48. In terms of profitability, PHG's ROE is +0.09%, compared to PROF's ROE of -0.71%. Regarding short-term risk, PHG is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check PROF's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, ANIK has a market cap of 196.8M. Regarding current trading prices, PHG is priced at $25.99, while ANIK trades at $14.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas ANIK's P/E ratio is -18.72. In terms of profitability, PHG's ROE is +0.09%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, PHG is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check ANIK's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PHG is priced at $25.99, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PHG's ROE is +0.09%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, PHG is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check BSGM's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, APYX has a market cap of 179.6M. Regarding current trading prices, PHG is priced at $25.99, while APYX trades at $4.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas APYX's P/E ratio is -19.50. In terms of profitability, PHG's ROE is +0.09%, compared to APYX's ROE of -0.91%. Regarding short-term risk, PHG is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check APYX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, QTRX has a market cap of 179M. Regarding current trading prices, PHG is priced at $25.99, while QTRX trades at $3.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas QTRX's P/E ratio is -1.62. In terms of profitability, PHG's ROE is +0.09%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, PHG is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check QTRX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PHG is priced at $25.99, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PHG's ROE is +0.09%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PHG is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check MDGS's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, PHG is priced at $25.99, while EDAP trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas EDAP's P/E ratio is -5.80. In terms of profitability, PHG's ROE is +0.09%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, PHG is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check EDAP's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, INGN has a market cap of 170.8M. Regarding current trading prices, PHG is priced at $25.99, while INGN trades at $6.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas INGN's P/E ratio is -6.93. In terms of profitability, PHG's ROE is +0.09%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PHG is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check INGN's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PHG is priced at $25.99, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PHG's ROE is +0.09%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PHG is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.Check QIPT's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, CVRX has a market cap of 156M. Regarding current trading prices, PHG is priced at $25.99, while CVRX trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas CVRX's P/E ratio is -2.93. In terms of profitability, PHG's ROE is +0.09%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, PHG is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check CVRX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, NNOX has a market cap of 144.1M. Regarding current trading prices, PHG is priced at $25.99, while NNOX trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas NNOX's P/E ratio is -1.78. In terms of profitability, PHG's ROE is +0.09%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, PHG is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check NNOX's competition here

PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHG stands at 25.3B. In comparison, SNWV has a market cap of 135M. Regarding current trading prices, PHG is priced at $25.99, while SNWV trades at $15.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHG currently has a P/E ratio of 22.40, whereas SNWV's P/E ratio is 16.35. In terms of profitability, PHG's ROE is +0.09%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, PHG is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.Check SNWV's competition here